Button Text
Imagine
Imagine

Better, safer, lasting medication delivery.

Peabody Pharmaceuticals

A one and done solution for better patient outcomes

Peabody is a late-stage biotechnology company with a versatile lipid carrier system that delivers better, safer, lasting medications for healthier patients. The Peabody Lipid Carrier System (PLCS) provides consistent plasma concentrations and effective treatment when medication compliance is critical to patient outcome.

Safer for patients.

Safer for physicians.

Safer for public health.

MICHAEL GUARNIERI, PhD, MPH
FOUNDER
JOE HARRISON, MS
FATIMA BACHANI, FCAA
CFO
TIM TURNER
‍Board Member

As a Baltimore based company, we understand
first-hand the impact that the opioid epidemic has had on public health and the role that prescription drugs have played in this crisis.

The Peabody team is a group of scientific, financial, legal, and business experts with an established success record. Ask our CEO about Peabody’s solutions.

Schedule a call

Peabody Lipid Carrier System (PLCS)

Peabody Pharmaceuticals reformulates existing medications utilizing our patented lipid carrier system to safely deliver therapeutic drug levels continuously for up to 3 days with a single injection.

  • ◦ Controlled Drug Release
  • ◦ Longer Stability
  • ◦ High Drug Loading
  • ◦ Biocompatible/Biodegradable
  • ◦ No Toxicity
  • ◦ Ease of Scale Up

Introducing PBD-2021

Our lead development candidate, PBD-2021, is a registration-directed formulation of a potent analgesic, buprenorphine, for the treatment of acute post-operative pain. Buprenorphine is approved by the FDA for the treatment of chronic pain and Opioid Use Disorder. Buprenorphine is a safer and better tolerated alternative to commonly prescribed opioids  used to treat acute pain.

Taking the Risk out of Pain Management

Utilizing Peabody’s PLCS carrier, PBD-2021 is designed to address the problems of overdose, misuse, diversion, and accidental pediatric exposure inherent in current opioid prescribing. The acute pain market represents a therapeutic area of substantially unmet need.

Download Peabody's Investor Presentation